Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 351

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 351
---
ome information to, enabling more informed long -termhealth decisions aimed at minimizing the risk of chronic disease development. This includes insights into genetic ancestry origins and personal genetic health risks, presented through Polygenic Risk Scores (“PRS”), which provides a measure of disease risk based on genetic factors. Rewell also delivers insights on dietary intolerances, physical activity and rest optimization, and specific nutrient impact on gene function and longevity. For PRS reporting, we apply scores from the PGS Catalog, an open database of polygenic scores (PGS), calculated using low -passgenome sequencing followed by genotype imputation. This means that each PRS is validated with local genetic backgrounds, which we have done for Rewell in Argentina. Specifically, for cardiovascular disease PRS (PGS000018) and breast cancer PRS (PGS000001), validation studies were conducted with our genetic database for healthy individuals and patients diagnosed with cardiovascular disease or breast cancer, allowing us to implement validated PRS for these conditions on the Rewell platform. In Argentina, we offer Rewell as a direct -to -consumerand a business -to - business-to -consumer(B2B2C) service, commercialized through an e -commercesite and through select laboratories. Customers purchase a “Complete Profile Kit,” which includes materials and instruction for collecting saliva and stool samples. Once their samples are collected, customers may schedule a pickup and their samples are transported to our Argentine Wet -Labfor processing. Once 180 processed, customers can view their DNA and gut microbiome test results on our secure and proprietary digital platform. The results are processed using our bioinformatics pipeline, which incorporates our proprietary machine learning models and integrates them with our standard and proprietary databases. Results are categorized into sections such as nutrition, ancestry, health and prevention, immunity, among others, and are available for download and sharing. Customers are also given the option of allowing us to utilize their de -identifieddata to support our AI research and tool development, with most opting in. This data is integrated with third party data, allowing us to develop additional biomarkers for lifelong updates and enabling the future expansion of AI applications. To protect sensitive customer data used in research, we enforce security protocols including role -basedaccess controls, multi -factorauthentication, data encryption at rest and in transit, and data anonymization and pseudonymization prior to AI training and compliance checks. Health Management & Telemedicine Once results are received through our digital platform, customers may schedule one -on-oneonline sessions with specialists certified in nutrigen